Greenwich LifeSciences, Inc.
GLSIStock
$19.01+75.86%52W
Market Cap$288.43M
P/E—
Div yield—
Beta1.42
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-16.08%
Price vs S&P 500 (4W)-18.40%
VGM Score53.00
Market Capitalization$288.43M
Earnings Surprise History
Q4 25-0.58est. -0.33
Q1 26-0.39est. -0.34
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.13
4.13
4.13
4.13
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
GLSIGreenwich LifeSciences, Inc. | — | — | C | $19.01 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Greenwich LifeSciences is a clinical-stage biopharmaceutical company developing GLSI-100, an immunotherapy combining GP2 and GM-CSF to prevent breast cancer recurrence in patients with HER2/neu-expressing tumors, which represent approximately 75% of breast cancers. The company is advancing GLSI-100 through its Phase III Flamingo-01 trial and expanding operations into Europe with plans to establish up to 150 clinical trial sites globally.